MWM
REGN icon

Moran Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Moran Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.4M Sell
4,398
-202
-4% -$155K 0.1% 249
2025
Q4 		$3.55M Buy
4,600
+99
+2% +$67.2K 0.11% 234
2025
Q3 		$2.53M Sell
4,501
-89
-2% -$50.3K 0.08% 261
2025
Q2 		$2.41M Sell
4,590
-15,211
-77% -$8.49M 0.07% 268
2025
Q1 		$12.6M Buy
19,801
+123
+0.6% +$84.6K 0.42% 78
2024
Q4 		$14M Sell
19,678
-2,538
-11% -$2.13M 0.45% 80
2024
Q3 		$23.4M Buy
22,216
+2,572
+13% +$2.86M 0.72% 36
2024
Q2 		$20.6M Sell
19,644
-450
-2% -$436K 0.68% 39
2024
Q1 		$19.3M Sell
20,094
-427
-2% -$406K 0.63% 47
2023
Q4 		$18M Sell
20,521
-7
-0% -$5.76K 0.64% 44
2023
Q3 		$16.9M Sell
20,528
-312
-1% -$245K 0.65% 47
2023
Q2 		$15M Sell
20,840
-745
-3% -$574K 0.56% 66
2023
Q1 		$17.7M Sell
21,585
-401
-2% -$302K 0.67% 48
2022
Q4 		$15.9M Buy
+21,986
New +$16.2M 0.6% 49

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Moran Wealth Management's REGN Position: Q1 2026 in Review

Moran Wealth Management reduced its Regeneron Pharmaceuticals (REGN) stake by 4.4% in Q1 2026, selling an estimated $155K and leaving 4,398 shares worth $3.4M. The position accounts for 0.1% of the portfolio, ranked #249.

Moran Wealth Management first reported a position in REGN in Q4 2022 and has held it in 14 quarters since. The position peaked at $23.4M in Q3 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Moran Wealth Management held 4,398 shares of Regeneron Pharmaceuticals worth $3.4M as of Q1 2026.
  • Moran Wealth Management sold 202 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $155K.
  • Regeneron Pharmaceuticals made up 0.1% of Moran Wealth Management's portfolio in Q1 2026, its #249 holding.
  • Moran Wealth Management first reported a position in Regeneron Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
  • Moran Wealth Management's Regeneron Pharmaceuticals position peaked at $23.4M in Q3 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Moran Wealth Management's 13F filing for Q1 2026, filed 27 Apr 2026.